KR100241583B1 - 아미드 작용기를 갖는 인돌린 유도체, 그의 제조방법 및 그를 함유하는 약학적 조성물 - Google Patents

아미드 작용기를 갖는 인돌린 유도체, 그의 제조방법 및 그를 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR100241583B1
KR100241583B1 KR1019930701034A KR930701034A KR100241583B1 KR 100241583 B1 KR100241583 B1 KR 100241583B1 KR 1019930701034 A KR1019930701034 A KR 1019930701034A KR 930701034 A KR930701034 A KR 930701034A KR 100241583 B1 KR100241583 B1 KR 100241583B1
Authority
KR
South Korea
Prior art keywords
group
substituted
alkyl
compound
unsubstituted
Prior art date
Application number
KR1019930701034A
Other languages
English (en)
Korean (ko)
Inventor
바뇽 쟝
쁠루잔느 끌로드
세라딜-르갈 끌로딘
니사또 디노
또네르 베르나드
Original Assignee
디. 꼬쉬
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디. 꼬쉬, 사노피 filed Critical 디. 꼬쉬
Application granted granted Critical
Publication of KR100241583B1 publication Critical patent/KR100241583B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
KR1019930701034A 1991-08-02 1992-07-31 아미드 작용기를 갖는 인돌린 유도체, 그의 제조방법 및 그를 함유하는 약학적 조성물 KR100241583B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9109908 1991-08-02
FR91-09908 1991-08-02
FR9109908A FR2679903B1 (fr) 1991-08-02 1991-08-02 Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
PCT/FR1992/000758 WO1993003013A1 (fr) 1991-08-02 1992-07-31 Derives d'indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
KR100241583B1 true KR100241583B1 (ko) 2000-03-02

Family

ID=9415909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701034A KR100241583B1 (ko) 1991-08-02 1992-07-31 아미드 작용기를 갖는 인돌린 유도체, 그의 제조방법 및 그를 함유하는 약학적 조성물

Country Status (29)

Country Link
EP (1) EP0526348B1 (xx)
JP (1) JP2633085B2 (xx)
KR (1) KR100241583B1 (xx)
AT (1) ATE163289T1 (xx)
AU (2) AU658664B2 (xx)
BR (1) BR9205336A (xx)
CA (2) CA2093221C (xx)
CZ (1) CZ288173B6 (xx)
DE (1) DE69224450T2 (xx)
DK (1) DK0526348T3 (xx)
ES (1) ES2117038T3 (xx)
FI (2) FI104069B1 (xx)
FR (1) FR2679903B1 (xx)
HK (1) HK1008741A1 (xx)
HU (2) HUT68927A (xx)
IL (3) IL102703A (xx)
LT (1) LT3064B (xx)
LV (1) LV10091B (xx)
MX (1) MX9204487A (xx)
MY (1) MY110517A (xx)
NO (1) NO180047C (xx)
NZ (1) NZ243795A (xx)
PH (1) PH30661A (xx)
RU (1) RU2104268C1 (xx)
SG (1) SG47501A1 (xx)
SK (1) SK283463B6 (xx)
UA (1) UA27238C2 (xx)
WO (1) WO1993003013A1 (xx)
ZA (1) ZA925781B (xx)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
IL133641A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Compounds which inhibit leukocyte adhesion mediated by vla-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
HUP0002495A3 (en) * 1997-07-31 2001-01-29 American Home Prod Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
JP2001512139A (ja) * 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Vla−4が介在する白血球接着を阻害するスルホニル化ジペプチド化合物
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
FR2775598A1 (fr) 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
WO2000043371A2 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
KR100711840B1 (ko) 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Vla-4 관련 질환 치료용 아실 유도체
AU3348700A (en) * 1999-01-25 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2805536B1 (fr) * 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805992A1 (fr) * 2000-03-08 2001-09-14 Sanofi Synthelabo Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
AU1401902A (en) 2000-10-17 2002-04-29 Applied Research Systems Pharmaceutically active sulfanilide derivatives
US7056910B2 (en) 2000-11-28 2006-06-06 Astellas Pharma Inc. 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
JP4044740B2 (ja) * 2001-05-31 2008-02-06 信越化学工業株式会社 レジスト材料及びパターン形成方法
EP1458381B1 (en) 2001-12-20 2005-11-30 Applied Research Systems ARS Holding N.V. Triazoles as oxytocin antagonists
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1554239B1 (en) * 2002-10-11 2011-01-26 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
KR100874292B1 (ko) 2002-11-18 2008-12-18 케모센트릭스 아릴 술폰아마이드
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
ATE493405T1 (de) 2005-09-29 2011-01-15 Elan Pharm Inc Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
CA2851103A1 (en) 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP5135235B2 (ja) 2006-02-27 2013-02-06 エラン ファーマシューティカルズ,インコーポレイテッド Val−4によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物
MX2011011326A (es) 2009-04-27 2012-02-13 Elan Pharm Inc Antagonistas de piridinona de las integrinas alfa-4.
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
SK283463B6 (sk) 2003-08-05
NO931262L (no) 1993-05-26
FI931476A0 (fi) 1993-04-01
NZ243795A (en) 1995-04-27
FI980175A0 (fi) 1998-01-27
LTIP114A (en) 1994-06-15
LV10091B (en) 1995-04-20
SG47501A1 (en) 1998-04-17
LV10091A (lv) 1994-05-10
CA2206776C (en) 2002-02-26
CZ288173B6 (en) 2001-05-16
MY110517A (en) 1998-07-31
FI107048B (fi) 2001-05-31
FI931476A (fi) 1993-04-01
UA27238C2 (uk) 2000-08-15
HUT68927A (en) 1995-08-28
FI104069B (fi) 1999-11-15
NO180047B (no) 1996-10-28
WO1993003013A1 (fr) 1993-02-18
JP2633085B2 (ja) 1997-07-23
NO180047C (no) 1997-02-05
NO931262D0 (no) 1993-04-01
LT3064B (en) 1994-10-25
BR9205336A (pt) 1993-11-16
FI104069B1 (fi) 1999-11-15
ES2117038T3 (es) 1998-08-01
HK1008741A1 (en) 1999-05-14
IL117592A (en) 1999-04-11
PH30661A (en) 1997-09-16
FR2679903B1 (fr) 1993-12-03
DE69224450D1 (de) 1998-03-26
FI980175A (fi) 1998-01-27
EP0526348A1 (fr) 1993-02-03
CA2093221C (en) 1998-09-22
IL117592A0 (en) 1996-07-23
AU1154195A (en) 1995-05-04
CA2093221A1 (en) 1993-02-03
RU2104268C1 (ru) 1998-02-10
EP0526348B1 (fr) 1998-02-18
AU691223B2 (en) 1998-05-14
IL102703A (en) 1997-03-18
CA2206776A1 (en) 1993-02-03
MX9204487A (es) 1993-02-01
ATE163289T1 (de) 1998-03-15
ZA925781B (en) 1993-03-02
IL102703A0 (en) 1993-01-14
HU9300951D0 (en) 1993-06-28
JPH06501960A (ja) 1994-03-03
SK42693A3 (en) 1993-10-06
AU658664B2 (en) 1995-04-27
AU2475892A (en) 1993-03-02
CZ68293A3 (en) 1994-01-19
DK0526348T3 (da) 1998-11-23
HU211884A9 (en) 1995-12-28
FR2679903A1 (fr) 1993-02-05
DE69224450T2 (de) 1998-07-30

Similar Documents

Publication Publication Date Title
KR100241583B1 (ko) 아미드 작용기를 갖는 인돌린 유도체, 그의 제조방법 및 그를 함유하는 약학적 조성물
US5397801A (en) N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US5578633A (en) N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
JP4137159B2 (ja) セロトニン及びノルアドレナリン再取り込み阻害薬としてのn−ピロリジン−3−イル−アミド誘導体
US20070010457A1 (en) Caspase inhibitors and uses thereof
JP2000515517A (ja) 成長ホルモン放出特性を有する化合物
JP2000502085A (ja) レトロウイルスプロテアーゼ阻害化合物
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
KR20010034377A (ko) 칼륨 채널 억제제
WO2008053913A1 (fr) Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
WO1998041510A1 (fr) Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
JP3195381B2 (ja) N−スルホニルインドリン誘導体の製造方法および医薬組成物
JP4224979B2 (ja) インターロイキン12抑制剤
IL203956A (en) Indole-2-on-2 derivatives are positioned in position 3, their preparation and use for drug preparation
JPS6253976A (ja) 複素環式カルボン酸誘導体
JPWO2003029218A1 (ja) 新規含窒素化合物及びその用途
JP7158464B2 (ja) カリウムチャネル阻害剤としての置換ベンゾイミダゾール
WO1994018165A1 (en) Sulfonamide compounds as opioid k-receptor agonists
CA2407463C (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
BR112021014389A2 (pt) Derivados de carbamato e usos dos mesmos
WO2021129629A1 (zh) Zeste增强子同源物2抑制剂及其用途
WO2006018815A1 (en) Piperazine derivatives as adrenergic receptor antagonists

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031023

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee